Huperzine A - Biscayne Pharmaceuticals

Drug Profile

Huperzine A - Biscayne Pharmaceuticals

Alternative Names: BIS-001; BIS-001ER; INS-001

Latest Information Update: 03 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Harvard University
  • Developer Biscayne Pharmaceuticals
  • Class Alkaloids; Neuroprotectants; Nootropics; Sesquiterpenes
  • Mechanism of Action Acetylcholinesterase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dravet syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Epilepsy

Most Recent Events

  • 19 Oct 2017 Biscayne Neurotherapeutics plans a phase IIa trial for extended release formulation of huperzine A for Seizures in early 2018 (Trial profile 700281277)
  • 22 May 2017 Phase-I clinical trials in Epilepsy (In volunteers) in Australia (unspecified route) (NCT03156439)
  • 09 May 2017 Australian regulatory authority approves clinical trial application for a phase Ib trial of Huperzine A in Epilepsy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top